Analysts Offer Insights on Healthcare Companies: Relay Therapeutics (RLAY), Stryker (SYK) and Elutia (ELUT)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Relay Therapeutics (RLAY – Research Report), Stryker (SYK – Research Report) and Elutia (ELUT – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Relay Therapeutics (RLAY)
Bank of America Securities analyst Chi Meng Fong maintained a Buy rating on Relay Therapeutics today. The company’s shares closed last Wednesday at $10.80.
According to TipRanks.com, Fong is ranked #11344 out of 12127 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Relay Therapeutics with a $15.33 average price target, implying a 44.6% upside from current levels. In a report issued on February 28, TipRanks – Google also upgraded the stock to Buy with a $11.50 price target.
See today’s best-performing stocks on TipRanks >>
Stryker (SYK)
Bank of America Securities analyst Travis Steed maintained a Buy rating on Stryker today. The company’s shares closed last Wednesday at $345.78.
According to TipRanks.com, Steed is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Stryker with a $429.50 average price target, representing a 19.8% upside. In a report issued on March 5, William Blair also maintained a Buy rating on the stock.
Elutia (ELUT)
Lake Street analyst Frank Takkinen reiterated a Buy rating on Elutia today and set a price target of $5.00. The company’s shares closed last Wednesday at $1.09.
According to TipRanks.com, Takkinen is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Elutia with a $5.00 average price target.
